• 1
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74108.
  • 2
    Augustin H,Hammerer PG,Graefen M,Palisaar J,Daghofer F,Huland H,Erbersdobler A. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy. J Cancer Res Clin Oncol 2003; 129: 6628.
  • 3
    Schroder FH,Bangma CH. The European randomized study of screening for prostate cancer (ERSPC). Br J Urol 1997; 79 ( Suppl 1): 6871.
  • 4
    Schroder FH,Denis LJ,Roobol M,Nelen V,Auvinen A,Tammela T,Villers A,Rebillard X,Ciatto S,Zappa M,Berenguer A,Paez A, etal. The story of the european randomized study of screening for prostate cancer. BJU Int 2003; 92 ( Suppl 2): 113.
  • 5
    Auvinen A,Tammela T,Stenman UH,Uusi-Erkkila I,Leinonen J,Schroder FH,Hakama M. Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in finland. Br J Cancer 1996; 74: 56872.
  • 6
    Freedland SJ,Terris MK,Csathy GS,Kane CJ,Amling CL,Presti JC,Jr,Dorey F,Aronson WJ,Search Database Study Group. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy gleason grade and serum prostate specific antigen. J Urol 2004; 171(6 Part 1): 221520.
  • 7
    Gerdes J,Lemke H,Baisch H,Wacker HH,Schwab U,Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody ki-67. J Immunol 1984; 133: 171015.
  • 8
    Leonardi E,Girlando S,Serio G,Mauri FA,Perrone G,Scampini S,Dalla Palma P,Barbareschi M. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992; 45: 41619.
  • 9
    Kubota Y,Petras RE,Easley KA,Bauer TW,Tubbs RR,Fazio VW. Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 1992; 70: 26029.
  • 10
    Bettencourt MC,Bauer JJ,Sesterhenn IA,Mostofi FK,McLeod DG,Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156: 10648.
  • 11
    Mucci NR,Rubin MA,Strawderman MS,Montie JE,Smith DC,Pienta KJ. Expression of nuclear antigen ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst 2000; 92: 19412.
  • 12
    Haussler O,Epstein JI,Amin MB,Heitz PU,Hailemariam S. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum Pathol 1999; 30: 107786.
  • 13
    Bubendorf L,Sauter G,Moch H,Schmid HP,Gasser TC,Jordan P,Mihatsch MJ. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 43741.
  • 14
    Laitinen S,Martikainen PM,Tolonen T,Isola J,Tammela TL,Visakorpi T. EZH2, ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122: 595602.
  • 15
    Isola J,Auvinen A,Poutiainen M,Kakkola L,Jarvinen TA,Maattanen L,Stenman UH,Tammela T,Hakama M,Visakorpi T. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. J Urol 2001; 165: 156974.
  • 16
    Eichler K,Hempel S,Wilby J,Myers L,Bachmann LM,Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175: 160512.
  • 17
    Weldon VE,Tavel FR,Neuwirth H,Cohen R. Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J Urol 1995; 154: 10747.
  • 18
    Postma R,de Vries SH,Roobol MJ,Wildhagen MF,Schroder FH,van der Kwast TH. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 2005; 103: 70816.
  • 19
    Hoedemaeker RF,Rietbergen JB,Kranse R,van der Kwast TH,Schroder FH. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the european randomized study of screening for prostate cancer. World J Urol 1997; 15: 33945.
  • 20
    van der Kwast TH,Ciatto S,Martikainen PM,Hoedemaeker R,Laurila M,Pihl CG,Hugosson J,Neetens I,Nelen V,Di Lollo S,Roobol MJ,Maatanen L, et al. Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European randomized screening study for prostate cancer. Int J Cancer 2006; 118: 253842.
  • 21
    Zackrisson B,Aus G,Bergdahl S,Lilja H,Lodding P,Pihl CG,Hugosson J. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol 2004; 171: 15003.
  • 22
    Stamey TA,Freiha FS,McNeal JE,Redwine EA,Whittemore AS,Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71( 3 Suppl): 9338.
  • 23
    Allan RW,Sanderson H,Epstein JI. Correlation of minute (0.5 mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003; 170(2 Part 1): 3702.
  • 24
    Epstein JI,Walsh PC,Carmichael M,Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 36874.
  • 25
    Postma R,Schroder FH,van Leenders GJ,Hoedemaeker RF,Vis AN,Roobol MJ,van der Kwast TH. Cancer detection and cancer characteristics in the European randomized study of screening for prostate cancer (ERSPC)–section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52: 8997.
  • 26
    Vis AN,van Rhijn BW,Noordzij MA,Schroder FH,van der Kwast TH. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol 2002; 197: 14854.